Double hit lymphoma – so what?
Professor Andrew Davies (Southampton, UK) discussed his presentation on double hit lymphoma. Written by Christine Clark.
Professor Andrew Davies (Southampton, UK) discussed his presentation on double hit lymphoma. Written by Christine Clark.
Professor Bob Steele CBE (Dundee, UK) discusses the potential implementation of a National Screening Programme in the UK, and the view post-NELSON, as well as highlighting the next steps in… read more.
The use of tyrosine kinase inhibitors (TKIs) in the treatment of ALK-positive NSCLC is now well-established. Professor Ross Camidge (University of Colorado Cancer Centre, Denver, USA) described the lessons that… read more.
Dr Popat gives an update of the ongoing studies in mesothelioma in the UK
Dr Fiona McDonald (London, UK) discusses radical treatment for oligo metastatic NSCLC and if it should be the standard of care and Professor James Spicer (London, UK), the session Chair, gives… read more.
Professor Ahmed gives an overview of one of the sessions in the BTOG Translational Oncology Symposium.
Correvio Pharma has resubmitted a New Drug Application (NDA) to the US FDA seeking approval for Brinavess (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF).
Managing Hodgkin lymphoma in elderly patients can be challenging, given that trial data do not reflect the picture in elderly patients and performance status can vary widely. The… read more.
Gene expression profiling has shown that that the activated B-cell and germinal centre B-cell subtypes of diffuse large B-cell lymphoma are driven by different oncogenic pathways and this may… read more.
BEACOPP treatment offers considerable advantages in terms of overall survival and low dose regimens offer short, safe and effective treatment for newly-diagnosed advanced-stage HL patients ……
The launch of biosimilar rituximab provided an opportunity to save £300,000 per year but called for time-consuming intravenous administration that exceeded the capacity of the hospital unit. Off-site… read more.
Is CAR-T cell therapy a realistic treatment option for patients with large B cell lymphoma who otherwise have no curative options or an expensive new treatment that is… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.